A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial With a Blinded 104-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin ≥1500 mg in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
Latest Information Update: 13 Jan 2022
Price :
$35 *
At a glance
- Drugs Dapagliflozin (Primary) ; Saxagliptin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 16 Jun 2020 Results evaluating gender differences in diabetes distress comparing Dapagliflozin plus Saxagliptin to Glimepiride added to Metformin in poorly controlled Type 2 Diabetes, presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 17 Sep 2019 Status changed from active, no longer recruiting to completed.
- 07 Jun 2019 Trial has been completed in Czech Republic according to European Clinical Trials Database record.